Bas Peters

3.5k total citations
38 papers, 464 citations indexed

About

Bas Peters is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Bas Peters has authored 38 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Surgery. Recurrent topics in Bas Peters's work include Lung Cancer Treatments and Mutations (16 papers), Lipoproteins and Cardiovascular Health (9 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Bas Peters is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Lipoproteins and Cardiovascular Health (9 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Bas Peters collaborates with scholars based in Netherlands, United States and France. Bas Peters's co-authors include Olaf H. Klungel, Anke H. Maitland‐van der Zee, Franz M.N.H. Schramel, E.M.W. van de Garde, Anthonius de Boer, Bruno H. Stricker, Elisabeth A. Kastelijn, Harry J.M. Groen, Andréi S. Rodin and Cornelia M. van Duijn and has published in prestigious journals such as Scientific Reports, Annals of Oncology and European Respiratory Journal.

In The Last Decade

Bas Peters

33 papers receiving 461 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bas Peters Netherlands 15 167 149 142 94 69 38 464
Amy Damask United States 9 76 0.5× 151 1.0× 90 0.6× 131 1.4× 62 0.9× 14 492
Felipe Melo Cruz Brazil 13 354 2.1× 279 1.9× 66 0.5× 122 1.3× 96 1.4× 40 674
Myra F. Barginear United States 13 218 1.3× 68 0.5× 39 0.3× 132 1.4× 49 0.7× 29 540
Devron R. Shah United Kingdom 7 241 1.4× 187 1.3× 30 0.2× 190 2.0× 30 0.4× 8 599
Eisei Oda Japan 13 130 0.8× 40 0.3× 86 0.6× 97 1.0× 41 0.6× 27 496
Joan Minguet Germany 11 154 0.9× 166 1.1× 80 0.6× 150 1.6× 61 0.9× 18 567
Rakesh Chopra India 8 224 1.3× 164 1.1× 133 0.9× 48 0.5× 110 1.6× 14 558
Yu‐Tse Tsan Taiwan 10 93 0.6× 117 0.8× 195 1.4× 128 1.4× 266 3.9× 19 740
Jessica Ray United States 13 56 0.3× 98 0.7× 160 1.1× 269 2.9× 240 3.5× 18 599
Paul Gougis France 13 225 1.3× 81 0.5× 25 0.2× 96 1.0× 40 0.6× 44 483

Countries citing papers authored by Bas Peters

Since Specialization
Citations

This map shows the geographic impact of Bas Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bas Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bas Peters more than expected).

Fields of papers citing papers by Bas Peters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bas Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bas Peters. The network helps show where Bas Peters may publish in the future.

Co-authorship network of co-authors of Bas Peters

This figure shows the co-authorship network connecting the top 25 collaborators of Bas Peters. A scholar is included among the top collaborators of Bas Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bas Peters. Bas Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heine, Rob ter, Bas Peters, Nienke A. G. Lankheet, et al.. (2025). The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study. Clinical Lung Cancer. 26(4). 324–330.e3.
2.
3.
4.
Bonás, Montse Janssen, Janani Sundaresan, Ruth G.M. Keijsers, et al.. (2023). Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot Study. Lung. 201(6). 617–624. 2 indexed citations
5.
Peters, Bas, et al.. (2022). The potential for deprescribing in a palliative oncology patient population: a cross-sectional study. European Journal of Hospital Pharmacy. 31(1). 10–15. 2 indexed citations
6.
Mathijssen, Ron H.J., Anne‐Marie C. Dingemans, Vivianne C. G. Tjan‐Heijnen, et al.. (2022). 1130P Real-world data of osimertinib (osi) for the treatment of metastatic epidermal growth factor receptor (EGFR+) non-small cell lung cancer (NSCLC) patients (pts), with a focus on age, body mass index (BMI) and trough levels. Annals of Oncology. 33. S1067–S1068. 1 indexed citations
7.
Peters, Bas, Franz M.N.H. Schramel, Olaf H. Klungel, et al.. (2021). Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Scientific Reports. 11(1). 6306–6306. 67 indexed citations
8.
Kastelijn, Elisabeth A., et al.. (2021). Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer. Anticancer Research. 41(2). 869–876. 19 indexed citations
9.
10.
Peters, Bas, et al.. (2019). The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population. Pharmacogenetics and Genomics. 29(7). 179–182. 5 indexed citations
11.
12.
13.
14.
Peters, Bas, Martinus A.H. Capelle, Tudor Arvinte, & E.M.W. van de Garde. (2013). Validation of an automated method for compounding monoclonal antibody patient doses. mAbs. 5(1). 162–170. 19 indexed citations
15.
Keyser, Catherine E. de, Bas Peters, Matthijs L. Becker, et al.. (2013). The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. Pharmacogenetics and Genomics. 24(1). 43–51. 35 indexed citations
16.
Peters, Bas, Helmi Pett, Olaf H. Klungel, et al.. (2011). Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis. 217(2). 458–464. 36 indexed citations
17.
Peters, Bas, Andréi S. Rodin, Olaf H. Klungel, et al.. (2010). Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenetics and Genomics. 20(12). 766–774. 9 indexed citations
18.
Zee, Anke H. Maitland‐van der, Bas Peters, Amy I. Lynch, et al.. (2009). The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and Genomics. 19(5). 338–344. 14 indexed citations
19.
Peters, Bas, Olaf H. Klungel, Anthonius de Boer, & Anke H. Maitland‐van der Zee. (2009). Genetic determinants of response to statins. Expert Review of Cardiovascular Therapy. 7(8). 977–983. 17 indexed citations
20.
Peters, Bas, Anke H. Maitland‐van der Zee, Bruno H. Stricker, et al.. (2008). Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and Genomics. 18(7). 631–636. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amy Damask Breakdown of academic impact, for papers by Felipe Melo Cruz Breakdown of academic impact, for papers by Myra F. Barginear Breakdown of academic impact, for papers by Devron R. Shah Breakdown of academic impact, for papers by Eisei Oda Breakdown of academic impact, for papers by Joan Minguet Breakdown of academic impact, for papers by Rakesh Chopra Breakdown of academic impact, for papers by Yu‐Tse Tsan Breakdown of academic impact, for papers by Jessica Ray Breakdown of academic impact, for papers by Paul Gougis
Rankless by CCL
2026